Vanda Pharmaceuticals Adds Independent Director to Strengthen Board

Vanda ( (VNDA) ) just unveiled an announcement.

On April 22, 2026, Vanda Pharmaceuticals Inc. expanded its Board of Directors from six to seven members and appointed Charles C. Duncan, Ph.D., as an independent Class II director, with his initial term running until the 2026 annual shareholders’ meeting. Duncan will receive restricted stock units with an initial grant-date value of $390,000 that vest over four years, ongoing annual equity awards valued at $260,000 vesting after one year, a $50,000 annual cash fee, and standard indemnification consistent with other directors.

Duncan, a veteran biotechnology equity research analyst and President of life sciences advisory firm Sulci Advisors, brings nearly three decades of Wall Street and sector expertise, including leadership roles at Cantor Fitzgerald, Piper Jaffray and JMP Securities, with a focus on neurology, psychiatry and platform-enabled therapeutics. His addition further strengthens the independence and industry depth of Vanda’s board at a time when the company highlights recent product approvals and an expanding pipeline, underscoring its ambitions for continued growth and value creation for patients, payors and shareholders.

The most recent analyst rating on (VNDA) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.

Spark’s Take on VNDA Stock

According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.

The score is held back primarily by weak financial performance—deepening losses, heavy cash burn, and equity erosion—despite low leverage. Offsetting this are strong technical momentum and a balanced but improving business outlook from the earnings call, including revenue growth guidance and recent approvals, though near-term cash burn and execution risks remain significant.

To see Spark’s full report on VNDA stock, click here.

More about Vanda

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs and improve patients’ lives. The company has a long history of innovation in central nervous system disorders and markets products such as Fanapt, NEREUS and BYSANTI, while advancing a growing pipeline targeting CNS and other serious conditions.

Average Trading Volume: 2,488,794

Technical Sentiment Signal: Buy

Current Market Cap: $413.2M

See more data about VNDA stock on TipRanks’ Stock Analysis page.